Niclosamide has been shown to have activity against SARS-CoV-2 in vitro, but poor bioavailability has hindered clinical development. In this clinical trial, the authors show that the niclosamide nanohybrid CP-COV03 alleviates COVID-19 symptoms and reduces viral load, offering a promising therapeutic option.
- Jung Ho Kim
- Sungmin Kym
- Jun Yong Choi
